Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012]

Autor: M, Penka, J, Schwarz, P, Ovesná, L, Cervinek, P, Dulíček, D, Pospíšilová, J, Kissová, T, Pavlík

Publikováno v: Vnitrni lekarstvi. 59(6)

In the Czech Republic, anagrelide (Thromboreductin®) [29] is used according to the recommendations of the Czech Working Group on Myeloproliferative Disorders (CZEMP) for treatment of thrombocythemia associated with Ph negative myeloproliferative dis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8e25549096039f8941110c4afdcdc1be
https://pubmed.ncbi.nlm.nih.gov/23808749

Zobrazit plný text záznamu

[Prognostic significance of morphology in multiple myeloma]

Autor: M, Al-Sahmani, I, Trnavská, M, Antošová, L, Antošová, J, Kissová, B, Kaisarová, Z, Adam, A, Buliková, M, Penka, R, Hájek

Publikováno v: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 25(2)

Multiple myeloma is the second most common hematological disease caused by clonal proliferation of B cells. Evaluation of number of plasmocytes in the bone marrow is still one of the basic diagnostic criteria. The aim of this study was to verify if t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5324e5ca2cd888efe06ea7327f3a1f5f
https://pubmed.ncbi.nlm.nih.gov/22533884

Zobrazit plný text záznamu

[Thrombohaemorrhagic syndrome in patients with a myeloproliferative disease with thrombocythemia]

Autor: M, Penka, J, Kissová, A, Buliková, J, Zavrelová, J, Ovesná, T, Pavlík

Publikováno v: Vnitrni lekarstvi. 57(3)

Thrombohaemorrhagic syndrome is a clinical syndrome manifesting with concurrent bleeding and thrombosis. It is associated with a range of pathological states, typically with myeloproliferative diseases, paraproteinaemia, liver disease as well as diss

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bc539e71f4eb82386bd38e491a515fa7
https://pubmed.ncbi.nlm.nih.gov/21495413

Zobrazit plný text záznamu

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]

Autor: J, Schwarz, M, Penka, V, Campr, D, Pospísilová, L, Kren, L, Nováková, C, Bodzásová, Y, Brychtová, O, Cerná, P, Dulícek, A, Joniásová, J, Kissová, Z, Korístek, M, Schützová, I, Vonke, L, Walterová

Publikováno v: Vnitrni lekarstvi. 57(2)

In 2009, the recommendations of the Czech Collaborative Group for Ph- Myeloproliferative Diseases (CZEMP) for diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases (MPD), i.e., essential thrombocythemia (ET), polycythaemia vera (PV)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4f2684f21d42943933ccb0bcdf14b52b
https://pubmed.ncbi.nlm.nih.gov/21416852

Zobrazit plný text záznamu

[Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010]

Autor: M, Penka, J, Schwarz, P, Ovesná, A, Hlusí, Z, Korístek, M, Doubek, P, Dulícek, D, Pospísilová, J, Kissová, A, Buliková, T, Pavlík

Publikováno v: Vnitrni lekarstvi. 56(6)

In the Czech Republic, anagrelid is used according to the recommendations of the Czech Working Group on Myeloproliferative Disorders for treatment ofthrombocythaemias associated with chronic myeloproliferative disorders--mainly essential thrombocytha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::43f40fa5a0184b913d9dedc67eb8c939
https://pubmed.ncbi.nlm.nih.gov/20681462

Zobrazit plný text záznamu

[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin]

Publikováno v: Vnitrni lekarstvi. 55(11)

The registry of patients treated with Thromboreductin (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this drug since 2004. As of June 2009, the total number of patients was 549. The current analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::28dc68f7822efebcd25645ab17ee454d
https://pubmed.ncbi.nlm.nih.gov/20017445

Zobrazit plný text záznamu

[Rare diagnosis of CD4+56+ leukemia from dendritic cells type DC2]

Autor: M, Klabusay, M, Pevná, J, Kissová, M, Doubek, M, Heidekerová, J, Mayer, J, Vorlícek

Publikováno v: Casopis lekaru ceskych. 147(10)

CD4+56+ hematodermic neoplasm or leukemia from early plasmocytoid dendritic cells type DC2 was recognized by WHO-EORTC classification of cutaneous lymphomas as a separate entity related to the plasmacytoid precursor dendritic cell (pDC). This diagnos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8c2bccc6b9c1fc747a85ebdcd2806614
https://pubmed.ncbi.nlm.nih.gov/19177732

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání